Pricing Log in Create free account

ProPhase Labs, Inc. (PRPH) vs XWELL, Inc. (XWEL)

ProPhase Labs, Inc. and XWELL, Inc. are both Diagnostics & Research companies. XWELL, Inc. is the larger, with a market value of $6.1M against $1.2M — 5.2× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −43.5%. XWELL, Inc. has the higher net margin (−117.8% vs −717.4%) and the higher return on invested capital (0.00% vs −387.3%). Across the 17 metrics below, XWELL, Inc. leads on 11 and ProPhase Labs, Inc. on 6.

Valuation

Metric PRPH XWEL Diagnostics & Research median
P/E n/m n/m 34.52
P/S 0.04 0.17 4.24
P/B n/m 0.59 3.42
Price to free cash flow n/m n/m 33.51
EV/EBITDA n/m 0.12 23.44
EV/Sales 1.84 (0.06) 5.18
Earnings yield (25,845.00%) (933.33%) (1.50%)
Free cash flow yield (3,945.49%) (278.57%) 0.00%

Profitability

Metric PRPH XWEL Diagnostics & Research median
Gross margin 16.38% 34.34% 48.32%
Operating margin (498.73%) (61.31%) (5.68%)
Net margin (717.43%) (117.83%) (4.10%)
Free cash flow margin (175.22%) (47.65%) 0.00%
Return on equity (543.95%) (557.21%) 0.00%
Return on assets (45.53%) (155.10%) (6.05%)
Return on invested capital (387.30%) 0.00% 0.00%

Growth

Metric PRPH XWEL Diagnostics & Research median
Revenue growth (TTM) (43.52%) (7.58%) 8.99%
EPS growth (last fiscal year) 93.33% (38.80%) 20.36%
Revenue growth, 5-year CAGR (21.43%) 28.35% 7.30%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRPH XWEL Diagnostics & Research median
Debt to equity (1.82) 0.00 0.01
Current ratio 0.05 2.27 2.27
Net debt to EBITDA (0.74) (0.08) 0.68

Dividend

Metric PRPH XWEL Diagnostics & Research median
Dividend yield — — 0.67%
Payout ratio — — 0.20

Size

Metric PRPH XWEL Diagnostics & Research median
Market cap 1.17m 6.08m 2.22b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack